BRCA1 and BRCA2 Mutations are they Related to Breast Cancer in a Sample of Tunisian Population?-Juniper Publishers

Juniper Publishers-Open Access Journal of Cancer Therapy and Oncology

BRCA1 and BRCA2 Mutations are they Related to Breast Cancer in a Sample of Tunisian Population?


Authored by Awatef Msolly

Mutations in the BRCA1/BRCA2 genes account for varying proportions of breast cancer families studied, and demonstrate considerable variation in mutational spectra coincident with ethnic and geographical diversity. This work aimed to identify mutations in BRCA1 and BRCA2 genes to explore the existence of population-specific recurrent or founder mutations, in Tunisian breast cancer families. We have screened for germline mutations in seventeen Tunisian high-risk breast cancer patients using direct sequencing. Index patients, diagnosed before age 45, possessing a positive family history or bilateral breast cancer were asked for detailed information on family history of breast or any other cancer type in their families. One family out of 17 (6%) carried BRCA 1 mutations and no BRCA2 mutations was found. One recurrent mutation in BRCA 1 was identified, c.798-799delTT, which appear to represent founder mutation in this population. Thirty-one variants were considered of unknown clinical significance according to BIC and UMD-BRCA1/BRCA2 databases.

Comments

Post a Comment

Popular posts from this blog

Drivers of Precision Medicine: Liquid Biopsy and Next-Generation Sequencing

Image
Cancer Therapy & Oncology- Juniper Publishers                                                      Abbreviations cfDNA: Cell-Free DNA; NGS: Next-Generation Sequencing; WGS: Whole Genome Sequencing; WES: Whole Exome Sequencing; GH: Guardant Health; CT: Circulogene Theranostics Editorial Targeted therapy specifically aims at tumor genetic alterations s the hallmark of precision medicine. Companion diagnostic testing utilized to determine the presence or absence of certain oncogenic mutations prior to targeted treatment under the current medical guidelines will enable improved clinical outcome, and thus serves as a vital component for precision medicine. Standard clinical practice to assess genetic mutations in cancer patients has historically been through direct sampling of tumor tissue with biopsy or surgical resection. Unfortunately, tissue biopsy is one-time single-site sampling, painful, costly, and can miss the dynamics of tumor clonally evolution during disease progression. The
Read more

Recent Advance in Diagnosis, Pathogenesis and Risk Stratification of Essential Thrombocythemia

Image
Cancer Therapy & Oncology- Juniper Publishers                                               Abstract In the 2016 version of WHO classification, bone marrow morphology is critical in the distinction between ET and pre-PMF. Reticulin-fiber grading becomes central: grade 1 or less is needed for ET. Furthermore,  CALR  assessment must be performed in all ET patients without  JAK2  mutation. Some prognostic implications have been described for  CALR  mutations, i.e., a lower risk of thrombosis in ET. Abbreviations:  MPN: Myelo Proliferative Neoplasm; WHO: World Health Organization; JAK: Janus kinase; CALR: Calreticulin; bp: base pair; MPL: Myelo Proliferative Leukemia virus oncogene; TPO: Thrombo Protein; RARS-T: Refractory Anemia with Ring Sideroblasts associated with marked Thrombocytosis; PMF: Primary Myelo Fibrosis; IPSET: The International Prognostic Score for Essential Thrombocythemia; WBC: White Blood Cell; LMWH: Low-Molecular Weight Heparin; SVT: Splanchnic Vein Thrombosis Intro
Read more

A Young Woman with Coomb's Positive Severe Haemolytic Anaemia and Hodgkin Lymphoma that Responded Completely to Rituximab: A Case Report

Image
  Cancer Therapy & Oncology- Juniper Publishers                                                      Abstract Introduction Lymphoma has been historically divided into a Hodgkin and Non-Hodgkin variety. There are reported cases of Hemolytic Anemia in Non- Hodgkin Lymphoma but Hodgkin Lymphoma very rarely also present with Hemolytic Anemias. Case presentation A 27-year-old African woman presented with chronic fatigue, dyspnoea, jaundice and Splenomegalie. Her blood work revealed severe anaemia (haemoglobin, 4.9 g/dl) with biochemical evidence of haemolysis. A direct Coomb's test was reported positive. A biopsy of the lymph nodes in the neck confirmed Hodgkin Lymphoma. Initial therapy consisted of intravenous methyl prednisolone and switched over to Oral Prednisolone. However, the patient came back with raised sugar levels and there was no clinically response. The patient continued to have lower hemoglobin levels and was transfused blood repeatedly. She was started on chemotherapy
Read more